

The Effect of Narrow Band Ultraviolet B on Tissue Levels of Lipocalin-2 in Psoriatic Patients and Controls.

A Thesis Submitted For Partial Fulfillment of MSc Degree in
Dermatology

By

Mohamed Mostafa Mohamed Soliman

(M.B.B.Ch.)

Supervised By

Dr. Rania Mohamed Mounir

Assistant Professor of Dermatology

Faculty of Medicine

Cairo University

Dr. Nesrin Samir

Assistant Professor of Dermatology

Faculty of Medicine

Cairo University

Dr. Laila Ahmed Rashed

Professor of Biochemistry

Faculty of Medicine

Cairo University

Faculty of Medicine

Cairo University

2016

محضر
 اجتماع لجنة الحكم على الرسالة المقدمة من
 الطبيب / محمد مصطفى محمد سليمان
 توظف للحصول على درجة الماجستير / الدكتوراه
 في الدراسات البيئية

تحت عنوان باللغة الإنجليزية :

باللغة العربية : - دور تأثير الإشعاع النووي في تنشيط ضيق الصدر
 مع مستوى الأيونات في الدم في مرضى الصدفية والاسهال

بدءا على موافقة الجامعة بتاريخ / / ٢٠٠٠ تم تشكيل لجنة الفحص والمناقشة للرسالة
 المذكورة أعلاه على النحو التالي :-

١. السيد الأستاذ الدكتور / رانيا محمد منير - أستاذة الدراسات البيئية عن المشرفين
٢. / دينا محمد منير - أستاذة الدراسات البيئية - ممتحن داخلي
٣. / رشا علي حبيب - أستاذة الدراسات البيئية والمختبرات الخارجية

بعد فحص الرسالة بواسطة كل عضو منفردا وكتابة تقارير منفردة لكل منهم انعقدت اللجنة مجتمعة في
 يوم الخميس بتاريخ ٧ / ٤ / ٢٠٠٦ بقسم الدراسات البيئية - مدرج العيادة الخارجية
 بكلية الطب - جامعة القاهرة وذلك لمناقشة الطالب في جلسة علنية في موضوع الرسالة والنتائج التي
 توصل إليها وكذلك الأسس العلمية التي قام عليها البحث .
 قرار اللجنة :

قبلت الرسالة

توقيعات أعضاء اللجنة :-
 المشرف الممتحن

الممتحن الداخلي

الممتحن الخارجي

د. رانيا محمد منير

د. دينا محمد منير

د. رشا علي حبيب

د. رانيا منير

د. رانيا منير

علم

Table of contents

ACKNOWLEDGMENT	I
ABSTRACT	II
LIST OF ABBREVIATIONS	IV
LIST OF FIGURES	VII
LIST OF TABLES	IX
INTRODUCTION	1
AIM OF THE WORK	3
REVIEW OF LITERATURE	1
Ch 1- Psoriasis	4
Ch 2- Lipocalin-2	18
Ch 3- Metabolic Syndrome	38
CH 4- Narrow band UVB	46
PATIENTS AND METHODS	51
RESULTS	59
DISCUSSION	85
RECOMMENDATIONS	92
SUMMARY	93
REFERENCES	96
الملخص العربي	116

Acknowledgment

First and foremost, thanks to GOD for giving me the strength and the ability to complete this work.

*I admire the help and guidance of **Prof. Dr. Rania Mohamed Monir**, Assistant Professor of dermatology, who inspired the idea of this work and for her continuous encouragement and valuable suggestions throughout this work.*

*I would like also to express my deep thanks and gratitude to **Prof. Dr. Nesrin Samir**, Assistant Professor of dermatology for her continuous help, support, advice and insightful comments throughout this work.*

*I am also grateful to **Prof. Dr. Laila Ahmed Rashed**, Professor of Biochemistry for her big effort on the tissue specimens of this work.*

*Also I'm so grateful to **Dr. Marwa Safwat**, Lecturer of Dermatology for her advices and support throughout this work.*

Finally, I would like to extend my deepest thanks to my family for their continuous support and encouragement, and my professors and colleagues who helped me throughout this work.

Mohamed Mostafa Soliman

Abstract

Background: Psoriasis is a chronic inflammatory skin disease characterized by red scaly plaques, which may occur on any site of the body; prevalence is about 2–3% in population. Lipocalin-2 has been recently identified as an adipokine present in the circulation; it is related to insulin resistance, obesity, atherosclerotic diseases and type 2 diabetes. Lipocalin-2 is assumed to be closely associated with the metabolic syndrome in addition to their role in innate immune response to bacterial infection, role in renal injury and in apoptosis. Narrow band ultraviolet B (NBUVB) is a good option in treatment of extensive cases of psoriasis.

Objective: Our aim was to estimate the tissue levels of lipocalin-2 in psoriasis and to find and possible association with metabolic syndrome criteria detected in our patients. The aim of the study was also to estimate the effect of NBUVB on tissue levels (lesional and non-lesional) of lipocalin-2 in psoriatic patients and to compare them with control subjects.

Patients and methods: This study was conducted on 25 psoriatic patients and 25 healthy controls. All patients and controls were subjected to clinical examination in which height, weight, body mass index, waist circumference and blood pressure were measured. Also tissue lipocalin-2 was done by ELISA technique before and after treatment with NBUVB. Lipid profile and fasting blood sugar were measured using regular laboratory methods.

Results: In this study we detected that tissue lipocalin-2 is a good prognostic indicator during treatment of psoriasis. No correlation was detected between tissue lipocalin-2 and disease extent or PASI score. Also there were no correlations between tissue lipocalin-2 and metabolic syndrome and related disorders. NBUVB is a good option in treating extensive cases of psoriasis.

Conclusion: Our patients with psoriasis were found to be at increased risk of metabolic disorders compared to healthy controls. NBUVB is a good treatment option of psoriasis; might be through reduction of tissue lipocalin-2. Tissue lipocalin-2 is related to disturbed differentiation rather than metabolic syndrome criteria in our patients' series.

KEY WORDS:

Psoriasis, lipocalin-2, metabolic syndrome, NBUVB.

List of Abbreviations

ACE	Angiotensin Converting Enzyme
AKI	Acute Kidney Injury
APCs	Antigen Presenting Cells
APP	Acute-Phase Protein
BBUVB	Broad-Band Ultraviolet-B
BCC	Basal Cell Carcinoma
BMI	Body Mass Index
BP	Blood Pressure
CD	Cluster Of Differentiation
CKDs	Chronic Kidney Diseases
CLA	Cutaneous Leukocyte Associated Antigen
DCs	Dendritic Cells
DNA	Deoxyribonucleic Acid
EGF-R	Epidermal Growth Factor Receptor
ELISA	Enzyme-Linked Immunosorbent Assay
FPG	Fasting Plasma Glucose
FPG	Fasting Plasma Glucose
GWAS	Genome-Wide Association Studies
HDL-C	High Density Lipoprotein-Cholesterol
HeLa cells	Henrietta Lacks Cells
HIV	Human Immunodeficiency Virus
HLA-Cw6	Human Leukocyte Antigen-Cw6
HPA-axis	Hypothalamic-Pituitary-Adrenal Axis
HRP	Horseradish Peroxidase
hs-CRP	High-Sensitivity C-Reactive Protein
ICAM-1	Intercellular Adhesion Molecule-1

IDF	International Diabetes Federation
IFN	Interferon
IFN-γ	Interferon- γ
Ig	Immunoglobulin
IGF-1	Insulin-Like Growth Factor 1
IL	Interleukin
IL- R	Interleukin Receptor
JNK	JunN-terminal Kinase
KA	Keratoacanthoma
kDa	Kilo Dalton
KGF	Keratinocyte Growth Factor
LDL-C	Low Density Lipoprotein-Cholesterol
LFA	Lymphocyte Function-Associated Antigen
LPS	Lipopolysaccharide
MED	Minimal Erythema Dose
MHC	Major Histocompatibility Complex
MMP	Matrix Metalloproteinase
mRNA	Messenger Ribonucleic Acid
MS	Metabolic Syndrome
NBUVB	Narrow-Band Ultraviolet-B
NF-kB	Nuclear Factor-Kappa B
NGAL	Neutrophil Gelatinase–Associated Lipocalin
NSAIDs	Non-Steroidal Anti-Inflammatory Drugs
OA	Osteoarthritis
OD	Optical Density
OGTT	Oral Glucose Tolerance Test
P.acne	Propionibacterium Acnes
PAI-1	Plasminogen Activator Inhibitor-1

PASI score	Psoriasis Area and Severity Index score
PCOS	Polycystic Ovary Syndrome
PCR	Polymerase Chain Reaction
PPAR-c	Peroxisome Proliferator-Activated Receptor-c
PPARγ	Peroxisome Proliferator-Activated Receptor- γ
PSORS	Psoriasis Susceptibility Loci
RBP-4	Retinol-Binding Protein-4
RT	Reverse Transcriptase
SCC	Squamous Cell Carcinoma
SD	Standard Deviation
SPSS	Statistical Package For The Social Sciences
TGF	Transforming Growth Factor
Th1	T Helper 1
Th17	T Helper 17
TIR	Toll/IL-1 Receptor
TMB	Tetramethylbenzidine
TNF-α	Tumor Necrosis Factor α
TP	Thymidine Phosphorylase
UV	Ultraviolet
UVR	Ultraviolet Rays
VEGF	Vascular Endothelial Growth Factor
WAT	White Adipose Tissue
SBP	Systolic Blood Pressure
DBP	Diastolic Blood Pressure
WC	Waist Circumference

List of Figures

Figure title	Page
Figure 1: Showed neutrophilic infiltrate, supra-papillary thinning and focal parakeratosis at psoriasis.	6
Figure 2: Phases of psoriasis pathogenesis.	10
Figure 3: The activation of naive CD4+ T cells by antigen-presenting cells (APCs) (Costimulation).	12
Figure 4: Characteristic features of the lipocalin fold. The eight b-strands of the antiparallel b-sheet are shown as arrows.	19
Figure 5: Show three-dimensional structure of lipocalin-2.	19
Figure 6: Schematic model of NGAL-mediated iron traffic.	24
Figure 7: Three-dimensional model shows the protein NGAL with the iron-enterochelin complex.	26
Figure 8: Th-17 pathway. Gray indicates gene downregulation.	49
Figure 9: Th1, Th17 and Th2 cytokines interactions	49
Figure 10: Sex prevalence among patients and controls	59
Figure 11: Obesity prevalence among patients	60
Figure 12: Diabetes prevalence among patients	62
Figure 13: Hypertension prevalence among patients	62
Figure 14: Dyslipidemia prevalence among patients	65

Figure 15: Prevalence of metabolic syndrome among patients	67
Figure 16: Comparison between psoriatic patients and control subjects	73
Figure 17: Comparison between psoriatic patients and control subjects regarding tissue lipocalin-2 level	74
Figure 18: Correlation between lesional lipocalin-2 levels before and after treatment	75
Figure 19: Correlation between non-lesional lipocalin-2 levels before and after treatment	76
Figure 20: Correlation between lesional and non-lesional lipocalin-2 levels before treatment	77
Figure 21: Correlation between lesional and non-lesional lipocalin-2 levels after treatment	78
Figure 22: Correlation between lesional lipocalin-2 levels before treatment and cholesterol level	80
Figure 23: Correlation between lesional lipocalin-2 levels before treatment and HDL-C level	80
Figure 24: Correlation between previously affected area lipocalin-2 levels after treatment and BMI	81
Figure 25: Correlation between previously affected area lipocalin-2 levels after treatment and TG level	81

List of Tables

Table title	Page
Table 1: Psoriasis Area and Severity Index (PASI) score.	53
Table 2: Demographic data of patients and controls.	61
Table 3: Clinical data of patients.	63
Table 4: Clinical data of controls.	64
Table 5: Laboratory data of patients and controls.	66
Table 6: Tissue lipocalin-2 levels in patients and controls.	68
Table 7: Comparison of tissue lipocalin-2 levels in lesional and non lesional specimens, before and after treatment in patients.	69
Table 8: Comparison of tissue lipocalin-2 levels in lesional and non lesional specimens, before and after treatment in patients.	69
Table 9: Comparison between PASI scores before and after treatment in patients.	70
Table 10: Comparison of tissue lipocalin-2 levels, PASI score before, between MS patients and non-MS patients.	70
Table 11: Comparison of tissue lipocalin-2 levels before and after treatment between dyslipidemic patients and non-dyslipidemic patients.	71
Table 12: Comparison between males and females psoriatic patients.	72
Table 13: Comparison between patients and control subjects.	73

Table 14: Correlation between lesional lipocalin-2 levels before and after treatment.	74
Table 15: Correlation between non-lesional lipocalin-2 levels before and after treatment.	75
Table 16: Correlation between lesional and non-lesional lipocalin-2 levels before treatment.	76
Table 17: Correlation between lipocalin-2 levels in previously affected specimens in relation to its levels in non-lesional specimens after treatment.	77
Table 18: Correlation of lesional lipocalin-2 before and after treatment in relation to demographic, anthropometric, clinical and laboratory data.	79
Table 19: Correlation of non-lesional lipocalin-2 before and after treatment in relation to demographic, anthropometric, clinical and laboratory data.	82
Table 20: Patients Master Table.	83
Table 21: Controls Master Table.	84

Introduction

Psoriasis is a chronic skin disease that affects about 1.5% of the Caucasian population. It is a disease that affects the skin, mucous membranes, nails and joints. It is characterized by typical macroscopic and microscopic skin alterations (*Sabat et al., 2007a*). Psoriatic lesions are sharply demarcated, red and slightly raised lesions with silvery-white scales (the most common presentation), it can also be presented as pustular lesions of varying extent. Occasionally, the entire skin can become involved, leading to erythroderma or exfoliative dermatitis (*Bos and De Rie, 1999*).

The pathogenesis of psoriasis is diverse; it includes cellular alterations in the skin with marked hyperplasia of the epidermis, altered keratinocytes differentiation and angiogenesis. The infiltrate is composed of skin-infiltrating CD4+ memory T-cells predominantly showing a T helper 1 (Th1) phenotype, neutrophils, macrophages, and increased numbers of dendritic cells (*Chamian et al., 2005*).

Although the precise pathomechanism of psoriasis remains unknown, various cytokines and growth factors are involved in this disease (*Griffiths and Barker 2007*).

Lipocalin-2, or neutrophil gelatinase-associated lipocalin (NGAL) (*Kjeldsen et al., 1993*), is a 25-kDa secretory glycoprotein that was originally identified in mouse kidney cells and human neutrophil granules. In addition to neutrophils, lipocalin-2 is expressed in several other tissues, including liver, lung, kidney, adipocytes, and macrophages (*Meheus et al., 1993*).

Several inflammatory stimuli, such as lipopolysaccharides and interleukin (IL) 1b, can markedly induce lipocalin-2 expression and secretion in these cells (*Jayaraman et al., 2005*).

Although lipocalin-2 was identified more than a decade ago, the physiologic functions of this protein remain poorly understood. Previous studies have focused on the role of this protein in the innate immune response to bacterial infection and in apoptosis (*Flo et al., 2004*). Previous reports suggested that lipocalin-2 might be a sensitive biomarker for early renal injury, also both clinical and experimental evidence demonstrated that circulating lipocalin-2 is a marker for obesity and its associated pathologies (*Mishra et al., 2005*).

Adipose tissue is now considered an endocrine organ secreting different cytokines known as adipocytokines including IL6, IL8, tumor necrosis factor (TNF)- α , as obesity is a state of chronic inflammation (*Engström et al., 2003*). Thus, lipocalin-2 plays a role in inflammatory processes. It is assumed that aberrant secretion of adipocytokines induces metabolic syndrome, which is a strong predictor of cardiovascular disease, diabetes mellitus and coronary heart disease (*Eckel et al., 2005*).

Previous studies also reported higher tissue and serum levels of lipocalin-2 in psoriatic patients compared to healthy control subjects (*El-Hadidi et al., 2014*).

Narrow-band ultraviolet-B (NB-UVB) phototherapy is an effective treatment for psoriasis through downregulation of Th17 pathway in psoriatic epidermis and strong inhibition of type 1 and type II interferon (IFN) signaling pathways which are critical in the pathogenesis of psoriasis (*Rácz et al., 2011*).